State Street Holds 4.8% Of Iovance — The Cancer-Therapy Company's Sales Outpace Last Year
The passive position covered 21,695,003 shares, while Iovance's third-quarter net loss narrowed to $22.3 million.
State Street reported a 4.8% stake in Iovance Biotherapeutics, which develops and sells cell therapies for solid tumor cancers, in a passive ownership disclosure filed Tuesday. The position covered 21,695,003 shares as of September 30, against a backdrop of rising revenue and smaller losses at the cancer-treatment company.
Sales Improved, Shares Fell
Iovance reported third-quarter revenue of $121.5 million, compared with $67.5 million a year earlier. Its net loss narrowed to $22.3 million from $91.3 million.
The company attributed sales growth to Amtagvi and Proleukin. Amtagvi contributed about $102 million of quarterly revenue, and Iovance reiterated its full-year revenue forecast of $410 million to $420 million.
The stock's performance told a different story: IOVA shares fell about 38% over the 30 days before the third-quarter report. Bailey Pemberton wrote in Yahoo Finance commentary that investors had been disappointed after Amtagvi's 2025 commercial launch.
Iovance's market value was $3.8 billion as of 8:45 a.m. ET Tuesday.
A Passive Position, Not A Control Bid
State Street certified that the shares were held through ordinary business activity, rather than for the purpose or effect of changing or influencing Iovance's control.
The reported stake uses the disclosure's beneficial-ownership basis. State Street listed shared voting power over 20,523,410 shares and shared power to dispose of 21,695,003 shares.
Treatment Built From Patients' Immune Cells
Iovance's tumor infiltrating lymphocyte therapy uses each patient's own immune cells. Amtagvi is an individualized, one-time T cell treatment for adults with previously treated advanced melanoma, approved in the United States and Canada and administered through authorized treatment centers.
Its other commercial product, Proleukin, is an interleukin-2 drug used in the Amtagvi regimen and other applications. Iovance produces its cell therapies at its Philadelphia, Pennsylvania, manufacturing center; its research pipeline includes lung cancer and melanoma trials.
State Street's disclosure records a passive ownership position while Iovance works toward its reiterated full-year sales forecast.
Sources
- SCHEDULE 13G — STATE STREET CORPORATION re: IOVANCE BIOTHERAPEUTICS INC (IOVA) — SEC EDGAR
- Barclays, Deutsche Bank Reveal Stakes In Retail-Favorite Cancer Stocks SLS, IBRX And IOVA — Geode Adds More — Yahoo Finance
- Iovance Biotherapeutics (IOVA) Q3 Earnings Sharpen Focus On Margin Recovery — Yahoo Finance